🔗 Share this article

While the United States undertakes historic changes to its vaccine recommendations, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by expressing skepticism about Covid vaccinations during the pandemic and has zeroed in on alleged fatalities after Covid immunization in her short position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Immunization Program

Agency leaders were set to announce major revisions to the pediatric vaccine schedule recently, synchronizing the US with the Danish vaccine program, it is understood – a substantial departure that would place the US out of step with many the world with no evidence for improved outcomes. The announcement has been delayed until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is scheduled to present at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this year.

A New Direction at the Regulatory Body

This interim role may indicate a closer partnership between the drug and biologics branches as Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a renewed priority upon rolling back long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing some pediatric immunization guidelines in the US to become more similar to Denmark, a nation with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

In her initial statements, she has continued to focus on immunizations – usually the purview of Dr. Prasad, director of the FDA’s CBER – rather than medication approval.

Questions Over Background

Dr. Høeg has little discernible background in medication creation, approval processes or administrative roles, which has been standard for previous leaders of the biologics center. She has served at the FDA as a key advisor to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, said Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a major agency. She has no expertise in drug approvals.”

Past commissioners of the center would “understand legal statutes and the research of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who headed CBER have had.”

CDER has an immense portfolio at the FDA, the former commissioner stated.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and more, and every single one need to be looked after,” she said. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a major administrative component to the role, which supervises over 5,000 employees. “It is a massive management job, if you execute it properly,” the former official said.

Official Statement and Contentious Policies

In response to concerns about Dr. Høeg's fitness for the role and whether this appointment indicates more teamwork among FDA leaders on immunizations, a spokesperson stated that the “questions are based on incorrect presumptions”.

“This background aligns with the duties of her job,” the official said, citing the period Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial expedited review system, a controversial rapid medication authorization process that allegedly worried her preceding directors. “By what process are these medications being picked for this voucher program? Who is making the choices?” Dr. Howard asked. “There is a lot of lack of transparency happening at the agency right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of most medications, aside from immunizations.”

Documented Track Record on Vaccines

With immunizations, Dr. Høeg has a clearer, if troubling, past, critics said. She released a study using non-validated crowd-sourced reports to determine the incidence of heart inflammation following COVID-19 vaccination. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccinations are more dangerous than they are.

Part of her “wish list” for the new administration featured changing rules for new vaccines and discontinuing “unnecessary” immunizations, she remarked post-election on a podcast. At the agency, Dr. Høeg has according to sources suggested excluding adolescent males from obtaining COVID-19 vaccinations.

“She’s an thorough dogmatist who commences with her preconceived notions and reverse-engineers to accommodate the evidence in a very disingenuous, fraudulent manner,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined fellow dissenters, {like|